Hołody Łukasz, Kunikowska Jolanta, Braziewicz Janusz
Zakład Medycyny Nuklearmej z Ośrodkiem PET Świętokrzyskie Centrum Onkologii, Artwińskiego 3, 25-734 Kielce.
Nucl Med Rev Cent East Eur. 2018;21(2):113-114. doi: 10.5603/NMR.a2018.0020. Epub 2018 Jun 29.
Breast cancer is the most common cancer in women in the western world. The estrogen receptor (ER) is expressed in two thirds of newly diagnosed breast cancers, so hormonal treatment is performed only in the receptor positive patients. The most successful ER imaging radiopharmaceutical in PET techniques is 16α-[18F]-flouro-17β-estradiol (¹⁸F-FES). The diffuse large B cell lymphoma (DLBCL) is one of the most common NHL, however, non-Hodgkin lymphoma constitutes only 4% of all primary cancers in women. The typical staging of disease is done using 18-fluorodeoksyglukose (¹⁸F-FDG) PET/CT.
乳腺癌是西方世界女性中最常见的癌症。雌激素受体（ER）在三分之二新诊断的乳腺癌中表达，因此仅对受体阳性患者进行激素治疗。PET技术中最成功的ER成像放射性药物是16α-[18F]-氟-17β-雌二醇（¹⁸F-FES）。弥漫性大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤之一，然而，非霍奇金淋巴瘤仅占女性所有原发性癌症的4%。疾病的典型分期使用18-氟脱氧葡萄糖（¹⁸F-FDG）PET/CT进行。
